Li Hong, Li Na, Xiang Qin, Zhou Yan
Department of Radiology, Renhe Hospital, Three Gorges University, Yichang, Hubei 443001, P.R. China.
Exp Ther Med. 2014 Aug;8(2):642-646. doi: 10.3892/etm.2014.1767. Epub 2014 Jun 6.
The aim of the present study was to investigate the value of apparent diffusion coefficients (ADCs) measured with magnetic resonance (MR) diffusion-weighted imaging (DWI) in evaluating liver fibrosis and curative effects on hepatocellular carcinoma (HCC) following transcatheter arterial chemoembolization (TACE) with low doses of chemotherapy. In total, 84 patients with HCC not recommended for surgical resection underwent TACE. The patients were divided into small dose (n=46) and conventional dose (n=38) chemotherapy groups, and underwent MR-DWI prior to and following TACE. Examination of the four liver fibrosis indexes, hyaluronate, laminin, human procollagen type-III and collagen type-IV, as well as ADC values (b=600 sec/mm), was conducted in the two groups. With small dose chemotherapy, the ADC values were not significantly different preoperatively and postoperatively (P>0.05). By contrast, with a conventional dose, statistically significant differences were observed between the preoperative and postoperative ADC values (P<0.01). ADC values in the small and conventional dose chemotherapy groups prior to the first cycle of TACE were 1.613±0.133×10 and 1.488±0.248×10 mm/sec, respectively, while following four cycles of TACE, the ADC values were 1.598±0.147×10 and 1.206±0.222×10 mm/sec, respectively. With regard to chemotherapy, the ADC values before and after TACE were significantly different (P<0.05). A significant negative correlation was observed between the ADC values and the fibrosis stage (P<0.05). Therefore, hepatic MR-DWI plays a key role in evaluating liver fibrosis following TACE with low doses of chemotherapy, resulting in improved curative effects of TACE.
本研究的目的是探讨磁共振(MR)扩散加权成像(DWI)测量的表观扩散系数(ADC)在评估肝纤维化以及低剂量化疗经动脉化疗栓塞术(TACE)治疗肝细胞癌(HCC)疗效中的价值。总共84例不建议手术切除的HCC患者接受了TACE治疗。患者被分为小剂量(n = 46)和常规剂量(n = 38)化疗组,并在TACE前后接受MR-DWI检查。对两组患者进行了四项肝纤维化指标(透明质酸、层粘连蛋白、人III型前胶原和IV型胶原)以及ADC值(b = 600秒/毫米²)的检测。小剂量化疗时,术前和术后ADC值无显著差异(P>0.05)。相比之下,常规剂量化疗时,术前和术后ADC值存在统计学显著差异(P<0.01)。TACE第一个周期前,小剂量和常规剂量化疗组的ADC值分别为1.613±0.133×10⁻³和1.488±0.248×10⁻³毫米²/秒,而在四个周期的TACE后,ADC值分别为1.598±0.147×10⁻³和1.206±0.222×10⁻³毫米²/秒。关于化疗,TACE前后的ADC值有显著差异(P<0.05)。ADC值与纤维化分期之间存在显著负相关(P<0.05)。因此,肝脏MR-DWI在评估低剂量化疗TACE后的肝纤维化中起关键作用,从而提高了TACE的疗效。